Drug Profile
Research programme: decoy oligonucleotide therapies - Valerio Therapeutics
Latest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator Onxeo SA
- Developer Valerio Therapeutics
- Class Antineoplastics; Oligonucleotides
- Mechanism of Action DNA repair inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Cancer in France (Parenteral)
- 25 Oct 2018 Onxeo plans preclinical studies for its drug candidate from the programme in 2019
- 27 Jun 2017 Onxeo receives patent protection for platON™ platform of decoy oligonucleotides and its potential applications in USA